Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#17 of 3,498)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 51 news stories from 51 outlets.

/PRNewswire/ -- Replimune Group Inc. announced today a key addition to its senior leadership team as it progresses its…

SOURCE Replimune Group Inc. WOBURN, Massachusetts Replimune Group Inc. announced today a key addition to its senior leadership…

SOURCE Replimune Group Inc. WOBURN, Massachusetts Replimune Group Inc. announced today a key addition to its senior leadership…

SOURCE Replimune Group Inc. WOBURN, Massachusetts Replimune Group Inc. announced today a key addition to its senior leadership…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 47 additional news stories.